1
|
Crayle JI, Rampersaud E, Myers JR, Wuu J, Taylor JP, Wu G, Benatar M, Bedlack RS. Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype. Neurology 2024; 103:e209696. [PMID: 39079071 PMCID: PMC11286288 DOI: 10.1212/wnl.0000000000209696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 05/29/2024] [Indexed: 08/02/2024] Open
Abstract
BACKGROUND AND OBJECTIVES The term "ALS Reversal" describes patients who initially meet diagnostic criteria for amyotrophic lateral sclerosis (ALS) or had clinical features most consistent with progressive muscular atrophy (PMA) but subsequently demonstrated substantial and sustained clinical improvement. The objective of this genome-wide association study (GWAS) was to identify correlates of this unusual clinical phenotype. METHODS Participants were recruited from a previously created database of individuals with the ALS Reversal phenotype. Whole-genome sequencing (WGS) data were compared with ethnicity-matched patients with typically progressive ALS enrolled through the CReATe Consortium's Phenotype-Genotype-Biomarker (PGB) study. These results were replicated using an independent ethnically matched WGS data set from Target ALS. Significant results were further explored with available databases of genetic regulatory markers and expression quantitative trait loci (eQTL) analysis. RESULTS WGS from 22 participants with documented ALS Reversals was compared with the PGB primary cohort (n = 103) and the Target ALS validation cohort (n = 140). Two genetic loci met predefined criteria for statistical significance (two-sided permutation p ≤ 0.01) and remained plausible after fine-mapping. The lead single nucleotide variant (SNV) from the first locus was rs4242007 (primary cohort GWAS OR = 12.0, 95% CI 4.1 to 34.6), which is in an IGFBP7 intron and is in near-perfect linkage disequilibrium with a SNV in the IGFBP7 promoter region. Both SNVs are associated with decreased frontal cortex IGFBP7 expression in eQTL data sets. Notably, 3 Reversals, but none of the typically progressive individuals (n = 243), were homozygous for rs4242007. The importance of the second locus, located near GRIP1, is uncertain given the absence of an associated effect on nearby gene transcription. DISCUSSION We found a significant association between the Reversal phenotype and an IGFBP7 noncoding SNV that is associated with IGFBP7 expression. This is biologically relevant as IGFBP7 is a reported inhibitor of the insulin growth factor-1 (IGF-1) receptor that activates the possibly neuroprotective IGF-1 signaling pathway. This finding is limited by small sample size but suggests that there may be merit in further exploration of IGF-1 pathway signaling as a therapeutic mechanism for ALS. TRIAL REGISTRATION INFORMATION This study was registered with ClinicalTrials.gov (NCT03464903) on March 14, 2018. The first participant was enrolled on June 22, 2018.
Collapse
Affiliation(s)
- Jesse I Crayle
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Evadnie Rampersaud
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Jason R Myers
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Joanne Wuu
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - J Paul Taylor
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Gang Wu
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Michael Benatar
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| | - Richard S Bedlack
- From the Department of Neurology (J.I.C., R.S.B.), Duke University School of Medicine, Durham, NC; Department of Neurology (J.I.C.), Washington University in Saint Louis, MO; Center for Applied Bioinformatics (E.R., J.R.M., G.W.), St. Jude Children's Research Hospital, Memphis, TN; Department of Neurology (J.W., M.B.), University of Miami Miller School of Medicine, FL; and Department of Cell and Molecular Biology (J.P.T.), St. Jude Children's Research Hospital, Memphis, TN
| |
Collapse
|
2
|
Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, Al-Chalabi A, Huynh W, Cudkowicz M, Talman P, Van den Berg LH, Dharmadasa T, Wicks P, Reilly C, Turner MR. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 2021; 17:104-118. [PMID: 33340024 PMCID: PMC7747476 DOI: 10.1038/s41582-020-00434-z] [Citation(s) in RCA: 138] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/05/2020] [Indexed: 12/11/2022]
Abstract
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s - a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches.
Collapse
Affiliation(s)
- Matthew C Kiernan
- Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
- Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
| | - Steve Vucic
- Sydney Medical School Westmead, University of Sydney, Sydney, New South Wales, Australia
| | - Kevin Talbot
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Christopher J McDermott
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
- NIHR Sheffield Biomedical Research Centre, Sheffield, UK
| | - Orla Hardiman
- Academic Neurology Unit, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
- National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland
| | - Jeremy M Shefner
- Department of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix, Creighton University, Phoenix, AZ, USA
| | - Ammar Al-Chalabi
- King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, UK
| | - William Huynh
- Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia
- Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Merit Cudkowicz
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Paul Talman
- Neurosciences Department, Barwon Health District, Melbourne, Victoria, Australia
| | - Leonard H Van den Berg
- Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands
| | - Thanuja Dharmadasa
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Paul Wicks
- Wicks Digital Health, Lichfield, United Kingdom
| | - Claire Reilly
- The Motor Neurone Disease Association of New Zealand, Auckland, New Zealand
| | - Martin R Turner
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| |
Collapse
|
3
|
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics 2019; 11:101. [PMID: 31300053 PMCID: PMC6624906 DOI: 10.1186/s13148-019-0700-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 07/03/2019] [Indexed: 12/13/2022] Open
Abstract
Peptides originating from different sources (endogenous, food derived, environmental, and synthetic) are able to influence different aspects of epigenetic regulation. Endogenous short peptides, resulting from proteolytic cleavage of proteins or upon translation of non-annotated out of frame transcripts, can block DNA methylation and hereby regulate gene expression. Peptides entering the body by digestion of food-related proteins can modulate DNA methylation and/or histone acetylation while environmental peptides, synthesized by bacteria, fungi, and marine sponges, mainly inhibit histone deacetylation. In addition, synthetic peptides that reverse or inhibit different epigenetic modifications of both histones and the DNA can be developed as well. Next to these DNA and histone modifications, peptides can also influence the expression of non-coding RNAs such as lncRNAs and the maturation of miRNAs. Seen the advantages over small molecules, the development of peptide therapeutics is an interesting approach to treat diseases with a strong epigenetic basis like cancer and Alzheimer’s disease. To date, only a limited number of drugs with a proven epigenetic mechanism of action have been approved by the FDA of which two (romidepsin and nesiritide) are peptides. A large knowledge gap concerning epigenetic effects of peptides is present, and this class of molecules deserves more attention in the development as epigenetic modulators. In addition, none of the currently approved peptide drugs are under investigation for their potential effects on epigenetics, hampering drug repositioning of these peptides to other indications with an epigenetic etiology.
Collapse
Affiliation(s)
- Yorick Janssens
- Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - Evelien Wynendaele
- Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - Wim Vanden Berghe
- Protein Science, Proteomics and Epigenetic Signaling (PPES), Department Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
| | - Bart De Spiegeleer
- Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.
| |
Collapse
|
4
|
Tarolli CG, Zimmerman GA, Goldenthal S, Feldman B, Berk S, Siddiqi B, Kopil CM, Chowdhury S, Biglan KM, Dorsey ER, Adams JL. Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Neurol Clin Pract 2019. [PMID: 32190415 DOI: 10.1212/cpj.0000000000000680 10.1212/cpj.0000000000000680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Use of video research visits in neurologic conditions is rising, but their utility has not been assessed in atypical parkinsonian syndromes. We sought to evaluate the diagnostic concordance between video-based vs self-reported diagnoses of multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and corticobasal syndrome. We also assessed patient satisfaction with video-based visits. Methods We conducted a study of video-based research visits in individuals with an atypical parkinsonian syndrome enrolled in The Michael J. Fox Foundation's Fox Trial Finder. Participants completed a recorded real-time video visit with a remote evaluator who was blinded to the participant's self-reported diagnosis. The investigator conducted a structured interview and performed standard assessments of motor function. Following the visit, the investigator selected the most likely diagnosis. The recorded visit was reviewed by a second blinded investigator who also selected the most likely diagnosis. We evaluated diagnostic concordance between the 2 independent investigators and assessed concordance between investigator consensus diagnosis and self-reported diagnosis using Cohen's kappa. We assessed participant satisfaction with a survey. Results We enrolled 45 individuals with atypical parkinsonian syndromes, and 44 completed the investigator-performed video assessment. We demonstrated excellent concordance in diagnosis between the investigators (κ = 0.83) and good reliability of self-reported diagnosis (κ = 0.73). More than 90% of participants were satisfied or very satisfied with the convenience, comfort, and overall visit. Conclusions Video research visits are feasible and reliable in those with an atypical parkinsonian syndrome. These visits represent a promising option for reducing burden and extending the reach of clinical research to individuals with these rare and disabling conditions.
Collapse
Affiliation(s)
- Christopher G Tarolli
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Grace A Zimmerman
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Steven Goldenthal
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Blake Feldman
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Sarah Berk
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Bernadette Siddiqi
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Catherine M Kopil
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Sohini Chowdhury
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Kevin M Biglan
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - E Ray Dorsey
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Jamie L Adams
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
5
|
Tarolli CG, Zimmerman GA, Goldenthal S, Feldman B, Berk S, Siddiqi B, Kopil CM, Chowdhury S, Biglan KM, Dorsey ER, Adams JL. Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Neurol Clin Pract 2019; 10:7-14. [PMID: 32190415 DOI: 10.1212/cpj.0000000000000680] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Accepted: 04/23/2019] [Indexed: 11/15/2022]
Abstract
Background Use of video research visits in neurologic conditions is rising, but their utility has not been assessed in atypical parkinsonian syndromes. We sought to evaluate the diagnostic concordance between video-based vs self-reported diagnoses of multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and corticobasal syndrome. We also assessed patient satisfaction with video-based visits. Methods We conducted a study of video-based research visits in individuals with an atypical parkinsonian syndrome enrolled in The Michael J. Fox Foundation's Fox Trial Finder. Participants completed a recorded real-time video visit with a remote evaluator who was blinded to the participant's self-reported diagnosis. The investigator conducted a structured interview and performed standard assessments of motor function. Following the visit, the investigator selected the most likely diagnosis. The recorded visit was reviewed by a second blinded investigator who also selected the most likely diagnosis. We evaluated diagnostic concordance between the 2 independent investigators and assessed concordance between investigator consensus diagnosis and self-reported diagnosis using Cohen's kappa. We assessed participant satisfaction with a survey. Results We enrolled 45 individuals with atypical parkinsonian syndromes, and 44 completed the investigator-performed video assessment. We demonstrated excellent concordance in diagnosis between the investigators (κ = 0.83) and good reliability of self-reported diagnosis (κ = 0.73). More than 90% of participants were satisfied or very satisfied with the convenience, comfort, and overall visit. Conclusions Video research visits are feasible and reliable in those with an atypical parkinsonian syndrome. These visits represent a promising option for reducing burden and extending the reach of clinical research to individuals with these rare and disabling conditions.
Collapse
Affiliation(s)
- Christopher G Tarolli
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Grace A Zimmerman
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Steven Goldenthal
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Blake Feldman
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Sarah Berk
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Bernadette Siddiqi
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Catherine M Kopil
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Sohini Chowdhury
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Kevin M Biglan
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - E Ray Dorsey
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| | - Jamie L Adams
- Department of Neurology (CGT, GAZ, KMB, JLA), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, SG, BF, ERD, JLA), University of Rochester Medical Center, NY; The Michael J. Fox Foundation for Parkinson's Research (SB, BS, CMK, SC), New York; and Early Phase Clinical Development (KMB), Neurosciences, Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
6
|
Bedlack RS, Wicks P, Vaughan T, Opie A, Blum R, Dios A, Sadri-Vakili G. Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotroph Lateral Scler Frontotemporal Degener 2019; 20:285-293. [PMID: 30663902 DOI: 10.1080/21678421.2018.1556698] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Objective: Lunasin, a soy peptide that reportedly alters histone acetylation in vitro, was associated with a single ALS reversal in the media. Following an ALSUntangled report, we sought to determine whether Lunasin altered histone acetylation and improved progression in people with ALS, and whether patient-centric trial design features might improve enrollment and retention. Methods: This single-center, year-long trial (NCT02709330) featured broad inclusion criteria, historical controls, primarily virtual data collection, and real-time results. Participants measured their own ALSFRS-R score, weight and perceived efficacy, and recorded these monthly on PatientsLikeMe. Blood tests at screening and month 1 assessed alterations in histone H3 and H4 acetylation. The protocol was published online, empowering patients outside the study to self-experiment. Results: Fifty participants enrolled in 5.5 months. Although this population had more advanced disease compared to other trials, retention and adherence were very high. There was no significant effect of Lunasin treatment on histone acetylation or disease progression. A cohort following our protocol outside the trial reported similar side effects and perceived effectiveness; however, their compliance with data entry was markedly lower. Conclusions: While Lunasin's lack of efficacy is disappointing, our novel trial design had the highest ALS trial enrollment rate ever recorded, with excellent retention and adherence. Low data density from patients who are self-experimenting outside a formal protocol casts doubt on the possibility of gathering useful information from unsupervised expanded access programs or "right to try" initiatives.
Collapse
Affiliation(s)
- R S Bedlack
- a Department of Neurology , Duke University , Durham , NC , USA
| | | | | | | | | | - Amanda Dios
- c NeuroEpigenetics Laboratory , MassGeneral Institute for Neurodegenerative Disease , Charlestown , MA , USA
| | - Ghazaleh Sadri-Vakili
- c NeuroEpigenetics Laboratory , MassGeneral Institute for Neurodegenerative Disease , Charlestown , MA , USA
| |
Collapse
|
7
|
Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, van den Berg LH, Crayle J, Bedlack R. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19:495-499. [DOI: 10.1080/21678421.2018.1457059] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
| | - Paul Mehta
- Agency for Toxic Substances and Disease Registry, National ALS Registry, Atlanta, GA, USA,
| | - Michael A. van Es
- Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands,
| | - Elijah Stommel
- Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,
| | - Vivian E. Drory
- Department of Neurology, Tel-Aviv Medical Center, Tel-Aviv, Israel, and
| | - Beatrice Nefussy
- Department of Neurology, Tel-Aviv Medical Center, Tel-Aviv, Israel, and
| | | | - Jesse Crayle
- School of Medicine, Duke University, Durham, NC, USA,
| | - Richard Bedlack
- Department of Neurology, Duke University and Durham VA Medical Center, Durham, NC, USA
| | | |
Collapse
|